The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Access to Data and Biospecimens, 2018Studying Methylation in the PPMI Cohort to Develop New Biomarkers
Study Rationale:
Because Parkinson's disease (PD) is a complex disease, it is difficult to accurately diagnose and treat. Biomarkers -- disease indicators that are critical missing links in the search... -
Research Grant, 2018Allosteric Targeting of LRRK2 Using Stapled Peptides
Study Rationale:
Mutations in the LRRK2 gene -- which alter enzymatic activity in the LRRK2 protein -- are associated with increased risk of Parkinson's disease. The protein is known to aggregate into... -
Target Advancement Program, 2018Role of 5-alpha Reductase 1 in the Therapy of Neurodegeneration and Levodopa-induced Dyskinesias
Study Rationale:
The two main types of the enzyme 5α-reductase (5αR) play a key role in the production of steroids in the brain and other organs. In pre-clinical testing, we found that inhibitors of... -
Access to Data & Biospecimens, 2018Rapid and Ultra-sensitive Quantitation of Disease-associated and Synuclein Seeds in Brain and Cerebrospinal Fluid by Syn RT-QuIC
Study Rationale:
The diagnosis and treatment of Parkinson’s disease (PD) would be aided by the availability of direct and highly sensitive tests for the abnormal clusters of the...
-
Improved Biomarkers and Clinical Outcome Measures, 2017Using Automatic Acoustic Speech Analysis and REM Sleep Behavior Disorder to Detect Individuals at High Risk of Parkinson's Disease and Other Alpha-synucleinopathies
Study Rationale:
Speech is an important indicator of motor function and movement coordination and can be extremely sensitive to the progression of neurologic diseases. The aim of this project is to... -
Oligomeric & pS129 Assay LEAPS, 2017Quantification of S129 Phosphorylated Alpha-synuclein Using the AlphaLISA® Immunoassay Platform
Study Rationale:
The alpha-synuclein protein is a key player in Parkinson’s disease (PD). Our ability to understand how this protein impacts the health of neurons in the brain is directly related to...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.